In the Journals

Juvéderm Voluma XC well-tolerated with high satisfaction, results last 2 years

Juvéderm Voluma XC is well-tolerated with high satisfaction for age-related midface volume deficit with results lasting up to 2 years.

At 15 sites in the United States and Canada patients were randomly assigned to either 20 mg/mL Juvéderm Voluma XC (n = 235) or to a no-treatment control (n = 47).

Treatment areas included the zygomaticomalar region, the anteromedial cheek and the submalar region.

At baseline and every 3 months for 2 years after the last treatment, researchers used the following assessments: the Global Aesthetic Improvement Scale (GAIS), satisfaction with midfacial regions and assessment of treatment goals set by the patients before treatment.

Mean injection volume, including both initial and touch-up treatments, was 6.68 mL. The mean injection volumes were 5.09 mL for initial treatment and 1.93 for touch-up treatment.

Almost all patients (92.8%) rated their midface volume as improved or much improved according to GAIS. Most of these (79%) of patients gave this same rating at 2 years.

At all time points, increases from baseline in mean scores were statistically significant.

Patients with greater injection volumes had increased satisfaction with facial appearance.

At 6 months, more than two-thirds of patients (67.8%) believed they achieved their treatment goals.

At 6 months following treatment with Juvéderm Voluma XC, 72.5% of patients perceived themselves as looking younger versus baseline and 55.4% at month 24.

Common treatment site responses were mild or moderate in severity and lasted no longer than 2 weeks for 55.4% of patients. – by Abigail Sutton

Disclosure: The researchers reported no relevant financial disclosures.

Juvéderm Voluma XC is well-tolerated with high satisfaction for age-related midface volume deficit with results lasting up to 2 years.

At 15 sites in the United States and Canada patients were randomly assigned to either 20 mg/mL Juvéderm Voluma XC (n = 235) or to a no-treatment control (n = 47).

Treatment areas included the zygomaticomalar region, the anteromedial cheek and the submalar region.

At baseline and every 3 months for 2 years after the last treatment, researchers used the following assessments: the Global Aesthetic Improvement Scale (GAIS), satisfaction with midfacial regions and assessment of treatment goals set by the patients before treatment.

Mean injection volume, including both initial and touch-up treatments, was 6.68 mL. The mean injection volumes were 5.09 mL for initial treatment and 1.93 for touch-up treatment.

Almost all patients (92.8%) rated their midface volume as improved or much improved according to GAIS. Most of these (79%) of patients gave this same rating at 2 years.

At all time points, increases from baseline in mean scores were statistically significant.

Patients with greater injection volumes had increased satisfaction with facial appearance.

At 6 months, more than two-thirds of patients (67.8%) believed they achieved their treatment goals.

At 6 months following treatment with Juvéderm Voluma XC, 72.5% of patients perceived themselves as looking younger versus baseline and 55.4% at month 24.

Common treatment site responses were mild or moderate in severity and lasted no longer than 2 weeks for 55.4% of patients. – by Abigail Sutton

Disclosure: The researchers reported no relevant financial disclosures.